Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.67 |
| ▸ | CTSB | P07858 | 3/20 | 0.67 |
| ▸ | CTSS | P25774 | 3/20 | 0.67 |
| ▸ | CTSK | P43235 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TACR1 | P25103 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629856 | 1.00 | CTSL (0.67) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL7220623 | 1.00 | CTSL (0.67) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL19017976 | 0.90 | CTSK (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL7919838 | 0.90 | CTSK (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL13949513 | 0.90 | CTSL (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL12406443 | 0.90 | CTSK (0.56) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL4228130 | 0.90 | CTSL (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL3709555 | 0.90 | CTSK (0.55) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL5859423 | 0.90 | CTSL (0.56) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL13724915 | 0.89 | CASP1 (0.57) | CTSLCTSBCTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657058-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-8735441-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8431571-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130041008-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8080576-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080545-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080576-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-5508407-A | TREATING OR PREVENTING INFECTION BY HIV | ELI LILLY AND COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| US-5502061-A | ENZYME INHIBITORS FOR HIV FOR TREATMENT OR PREVENTION OF AIDS | ELI LILLY AND COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| US-5491166-A | ENZYME INHIBITORS, VIRICIDES | ELI LILLY AND COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| EP-0652009-A1 | Identification and use of protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0609625-A1 | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0604184-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604186-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604182-A2 | Inhibitors of HIV protease useful for the treatment of Aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0526009-A1 | Inhibitors of hiv protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1993-02-03 | — | — | EP | disclosed |
| EP-0361341-A2 | Therapeutics for aids based on inhibitors of HIV protease | MILES INC. (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSS 169/4885 |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSS 169/4885 |
| US-20130041008-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSS 169/4885 |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | CTSL 724/4885CTSB 168/4885CTSS 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.